KMT2A and acute myeloid leukemia: CX-5461 showed therapeutical efficiency in mice bearing MYC-driven lymphomas [44], models of p53 wild type (WT) and mutated murine AML, including MLL-driven leukaemias which are refractory to current therapies [82], and multiple myeloma [87].